Overview

This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.

Eligibility

Inclusion Criteria:

• Diagnosed with heterozygous familial hypercholesterolemia
• Adult between 18 and 50 years old
• LDL cholesterol levels above 100 mg/dl (>2.6 mmol/L) at inclusion

Exclusion Criteria:

• Renal insufficiency, defined as eGFR < 30 ml/min
• History of atherosclerotic cardiovascular events
• Atrial fibrillation
• Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
• Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.